Explore

Trendline Trendline
NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment NTRX-07

NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment NTRX-07

NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment NTRX-07
Rapid Read Rapid Read
NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment with Positive Outcomes

NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment with Positive Outcomes

NeuroTherapia, Inc., a clinical-stage biotechnology company, has successfully completed its Phase 2a clinical trial for its lead molecule, NTRX-07, aimed at treating Alzheimer's Disease (AD). The trial, conducted over 28 days, focused on safety, pharmacokinetics, and clinical efficacy, while also assessing target engagement through biomarkers of neuroinflammation and neuronal function. Dr. Joseph Foss, Chief Medical Officer, reported that NTRX-07 was safe and well-tolerated, with drug exposure levels meeting expectations. Preliminary analysis of exploratory endpoints, including MRI and EEG, showed encouraging results, supporting further development of this treatment approach. The trial involved 48 subjects across five sites in Hungary, Poland, and the Czech Republic, managed by CRU Global.
Trendline Trendline
RoosterBio Partners with MineBio to Expand MSC and Exosome Solutions in China

RoosterBio Partners with MineBio to Expand MSC and Exosome Solutions in China

RoosterBio Partners with MineBio to Expand MSC and Exosome Solutions in China
Trendline Trendline
Jeito Capital Closes Record $1.2 Billion Fund for European Biopharma Investments

Jeito Capital Closes Record $1.2 Billion Fund for European Biopharma Investments

Jeito Capital Closes Record $1.2 Billion Fund for European Biopharma Investments
Trendline Trendline
Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trial, Aiming for Market Growth

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trial, Aiming for Market Growth

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trial, Aiming for Market Growth
Trendline Trendline
NeuroTherapia Completes Phase 2a Trial for Alzheimer's Disease Treatment

NeuroTherapia Completes Phase 2a Trial for Alzheimer's Disease Treatment

NeuroTherapia Completes Phase 2a Trial for Alzheimer's Disease Treatment
Trendline Trendline
Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials

Amgen's New Tepezza Formulation Shows Promise in Phase 3 Trials
Rapid Read Rapid Read
Westlake University Develops High-Throughput Platform for Covalent Protein Therapies

Westlake University Develops High-Throughput Platform for Covalent Protein Therapies

Researchers at Westlake University in China have developed a high-throughput platform for engineering fast-acting covalent protein therapeutics. This platform aims to address the kinetic mismatch in covalent protein drugs, which are typically cleared rapidly in vivo while forming slow covalent bonds. The new system combines yeast surface display with chemoselective protein modification, allowing for rapid and irreversible target engagement. The platform has been used to develop a covalent antagonist targeting PD-L1, named IB101, which shows strong antitumor activity in mouse models. Additionally, it has been applied to cytokine engineering, resulting in a covalent IL-18 variant, IB201, which enhances signaling strength and duration. The platform also demonstrated versatility by developing a covalent inhibitor targeting the receptor-binding domain of SARS-CoV-2, showing durable viral neutralization.
SB Nation SB Nation
Orioles live game chat: April 7 vs. Cubs, 3:10

Orioles live game chat: April 7 vs. Cubs, 3:10

Trevor Rogers day usually means good things for the Orioles.
Rapid Read Rapid Read
NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment, Shows Promising Results

NeuroTherapia Completes Phase 2a Trial for Alzheimer's Treatment, Shows Promising Results

NeuroTherapia, Inc., a clinical-stage biotechnology company, has announced the completion of its Phase 2a clinical trial for a novel treatment targeting Alzheimer's Disease (AD). The trial involved the administration of NTRX-07, the company's lead molecule, over a 28-day period in a double-masked, randomized setting. The primary focus was on safety, pharmacokinetics, and clinical efficacy, with additional assessments on target engagement through biomarkers of neuroinflammation and neuronal function. The trial, conducted across sites in Hungary, Poland, and the Czech Republic, enrolled 48 subjects. Preliminary results indicate that NTRX-07 is safe and well-tolerated, with no serious adverse events reported. Encouraging outcomes were observed in MRI and biomarker analyses, suggesting potential stabilization of neuroinflammation in AD patients.
Trendline Trendline
Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment

Evommune to Explore MRGPRX2 Inhibition for Migraine Treatment
Rapid Read Rapid Read
FDA Orders Recall of Wawa Beverages Due to Undeclared Milk Allergen Risk

FDA Orders Recall of Wawa Beverages Due to Undeclared Milk Allergen Risk

The Food and Drug Administration (FDA) has announced a recall of several Wawa-branded beverages due to the presence of an undeclared milk allergen. The affected products include Wawa Iced Tea Lemon, Wawa Iced Diet Tea Lemon, Wawa Diet Lemonade, and Wawa Fruit Punch, all in 16-ounce bottles. These drinks were sold across 123 stores in Delaware, Maryland, New Jersey, Pennsylvania, and Virginia. The recall was initiated after Wawa identified and corrected an equipment issue that may have led to the contamination. No adverse reactions have been reported so far, but the FDA advises consumers to dispose of the products and request a refund from Wawa.